Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [6001] Comparative breast tumor imaging to identify the expression of type I IGF receptor (IGF1R) by anti-IGF1R antibody-conjugated small molecule fluorophore or quantum dots in vivo.
  [6002] Surface functionalized nanoparticles for proximity-activated detection and imaging of breast cancer.
  [6004] Molecular targeting of HER2 for diagnosis and therapy of breast cancer.
  [6005] Metabolism-perfusion mismatch as assessed by PET varies with breast cancer phenotype and predicts response to neoadjuvant chemotherapy.
  [6006] DCE-MRI and dynamic FDG PET to monitor breast cancer response to neoadjuvant sunitinib in patients with locally-advanced breast cancer.
  [6007] Clinicopathological factors affected no 18FDG uptake in 18FDG-PET CT: only invasive ductal cancer.
  [6009] The sensitivity of multidisciplinary triple assessment for diagnosing breast cancer in a symptomatic breast clinic.
  [6010] Increase in mastectomies performed in patients in the community settings undergoing MRI.
  [6011] In vivo magnetic resonance imaging of the progression of murine ductal carcinoma in situ: finding timescales and predictors of future invasion.
  [6013] Novel roles of a transcription elongation regulator in mammary gland development and tumorigenesis.
  [6018] Palladin expression contributes to invasive motiliy in metastatic breast cancer cells.
  [6019] Decreased cell proliferation of breast cancer cells by genistein is caused by estrogen receptor related signaling molecules.
  [6020] Prevalence of BRCA1 and BRCA2 genes mutations in a sample of families with high risk of breast and ovarian cancer in Brazil.
  [6021] Involvement of notch and RUNX pathways in human breast cancer.
  [6023] Novel 7-mer peptide mediates nuclear targeting in MCF7 breast cancer cells.
  [6024] Effective metabolic intervention of breast cancer progression and metastasis.
  [6025] Obesity, insulin resistance and oxidative stress: implication for breast carcinogenesis.
  [6028] Expression of prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines and breast tissue and regulation of prostaglandin metabolism by calcitriol.
  [6030] mTOR modulates cellular fat metabolism by regulating stearoyl-CoA desaturase 1 transcription.
  [6031] Protein expression comparison and physiological profiling of matched pairs DCIS/normal and invasive/normal primary epithelial cells.
  [6032] HER-2 over expression mediates the transition to aerobic glycolysis and stress/REDOX signaling in progressively transformed human mammary epithelial cells.
  [6033] HER-2/neu expression/amplification is not stable during tumor progression. A single institution study with intrapatient comparisons years 1999 through to 2007.
  [6034] Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention.
  [6036] TOP2A mRNA expression in HER2 negative breast cancer.
  [6037] Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: long term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial.
  [6038] HOXB13 protein expression predicts the benefit of tamoxifen treatment in breast cancer patients.
  [6039] BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer.
  [6042] Lack of TIMP-1 tumor cell immunoreactivity predicts effect of adjuvant anthracycline based chemotherapy in patients (n=647) with primary breast cancer.
  [6043] Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657.
  [6044] Prognostic algorithm identified in node-negative early breast cancer patients predicts outcome also in node-positive patients treated with adjuvant chemotherapy.
  [6045] Hot flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen.
  [6046] Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840.
  [6047] p53 mutational status, but not immunohistochemical staining (IHC), is associated with a clinical response of the primary tumor in women receiving neoadjuvant docetaxel-capecitabine chemotherapy for locally advanced breast cancer.
  [6048] Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001.
  [6049] High amplified in breast cancer 1 is a significant predictor of improved response to adjuvant tamoxifen in premenopausal women.
  [6050] Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization.
  [6051] Progesterone receptor levels are associated with time to aromatase inhibitor treatment failure in estrogen receptor-positive advanced breast cancer.
  [6052] Circulating tumor cells and FDG-PET/CT: biological and functional methods for therapeutic monitoring in metastatic breast cancer.
  [6053] Comparison of MRI tumor volumetric and diameter measurements for predicting recurrence free survival in breast cancer patients undergoing preoperative chemotherapy.
  [6054] Tumor tissue levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) and survival following adjuvant chemotherapy in pre-menopausal lymph node-positive breast cancer patients (N=525).
  [6056] Diffuse optical spectroscopic imaging measures tumor functional response to bevacizumab: initial studies.
  [6057] Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer.
  [6058] HER2 amplification does not alter outcome in small (≤1 cm) tumors.
  [6059] Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines?
  [6060] Phosphatidyl-inositol-3-kinase Alpha catalytic subunit kinase domain mutations impart a favorable prognosis on estrogen receptor positive breast cancer through a mechanism that is independent of responsiveness to endocrine treatment.
  [6065] Ratio of cyclin-dependent kinase 1 (CDK1) activity to CDK2 activity after ex vivo paclitaxel treatment predicts response to paclitaxel in human breast cancer.
  [6066] Elevated mRNA expression of herstatin predicts poor outcome in patients with high-risk early breast cancer. A possible molecular predictor of treatment benefit in the context of a Hellenic cooperative oncology group trial.
  [6068] Reductions in tumor RNA integrity associated with clinical response to epirubicin/docetaxel chemotherapy in breast cancer patients.
  [6069] Response to neoadjuvant chemotherapy in patients with triple negative breast cancer.
  [6070] HER2 amplification predicts breast cancer recurrence but not overall survival.
  [6071] Breast cancer molecular classification using immunohistochemical surrogate markers predicts response to neoadjuvant chemotherapy.
  [6072] TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib.
  [6073] Immunoglobulin G fragment C gamma receptor (FcGR) polymorphisms and efficacy of single-agent trastuzumab in patients treated with metastatic breast cancer.
  [6074] Serum biomarker analysis in a phase II study of irinotecan in refractory metastatic breast cancer (MBC).
  [6075] A retrospective study of drug response indicator test (DRIT) as a predictive test for therapeutic treatment outcomes of advanced breast cancer patients (ABC).
  [6076] Breast cancer in the United States: the burden on an aging, changing nation.
  [6077] Survival among women with triple receptor-negative breast cancer and brain metastases.
  [6078] Prevalence of fibroadenomas in kidney-transplanted patients using cyclosporine A.
  [6080] Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients.
  [6081] Socio-economic deprivation independently predicts early recurrence in estrogen receptor positive breast cancer.
  [6082] Breast cancer mortality trends in the WEST compared to the EAST: lives gained, lives lost.
  [6083] Breast cancer mortality reduction in the western world: therapeutic versus diagnostic interventions. Implications for cancer care organization processes.
  [6084] Lifestyle, weight history, nutrition and breast cancer among non-gene carriers: a case-control study.
  [6086] Breast cancer and renal insufficiency.
  [6088] Increased incidence of breast cancer among young women: reality or overestimation?
  [6089] Obesity and postmenopausal breast cancer: impact on risk, tumour stage and survival in an Irish population.
  [6090] A clinico-pathological analysis of breast cancer patients with a family history.
  [6091] Survival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer.
  [6092] Clinical outcomes of obese low socioeconomic status women diagnosed with invasive breast cancer.
  [6093] Survival analisis in breast cancer's women in Santa Catarina, Brazil.
  [6094] Who calls the breast care nurses – the rich, the poor or the poorly?
  [6095] Modifications in breast cancer presentation patern in Goiânia, Brazil: descriptive analyzes of a population based of 15 years in a developing country.
  [6096] Ethnic and geographical variability of breast cancer at the Osh region in Kyrgyzstan.
  [6097] Obesity a significant risk factor for contralateral breast cancer ocurrence.
  [6098] Racial discripancies in breast cancer in urban hospital retrospective analysis.
  [6099] Triple-negative breast cancer and obesity in a rural Appalachian population.
  [6100] Cost-effectiveness of genetic testing for BRCA1 and BRCA2 mutations.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved